Exelixis: The Cash?Generating Biotech That I Think Deserves a Closer Look in 2026
Source: Motley Fool
2026-02-20 16:05:00 ET
While not the most popular biotech company on the market, Exelixis (NASDAQ: EXEL) has been quietly making a name for itself over the past five years, while delivering strong financial results and solid returns.
The good news is that the company could still have plenty of room to grow, and that's why it deserves a closer look this year. Let's dig deeper into Exelixis.
Image source: Getty Images.
Exelixis Inc.
NASDAQ: EXEL
EXEL Trading
-0.94% G/L:
$41.31 Last:
660,395 Volume:
$41.17 Open:
EXEL Latest News
February 28, 2026 04:57:00 am
3 Reasons Exelixis Stock Could Deliver Market?Beating Returns Over the Next Decade
February 24, 2026 04:05:00 pm
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
February 24, 2026 10:58:00 am
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
February 20, 2026 04:05:00 pm
Exelixis: The Cash?Generating Biotech That I Think Deserves a Closer Look in 2026
EXEL Stock Data
$11,614,618,641
260,551,394
1.54%
313
N/A
Biotechnology & Life Sciences
Healthcare
US
Alameda
